CN101703468A - Nano-emulsion of vitamin E oil and preparation method thereof - Google Patents
Nano-emulsion of vitamin E oil and preparation method thereof Download PDFInfo
- Publication number
- CN101703468A CN101703468A CN200910154931A CN200910154931A CN101703468A CN 101703468 A CN101703468 A CN 101703468A CN 200910154931 A CN200910154931 A CN 200910154931A CN 200910154931 A CN200910154931 A CN 200910154931A CN 101703468 A CN101703468 A CN 101703468A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- nanoemulsion
- emulsion
- emulsifier
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 54
- 229930003427 Vitamin E Natural products 0.000 title claims abstract description 50
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 239000011709 vitamin E Substances 0.000 title claims abstract description 50
- 235000019165 vitamin E Nutrition 0.000 title claims abstract description 50
- 229940046009 vitamin E Drugs 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 239000007957 coemulsifier Substances 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 13
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 210000003022 colostrum Anatomy 0.000 claims description 8
- 235000021277 colostrum Nutrition 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- -1 polyoxyethylene Polymers 0.000 claims description 5
- 235000010265 sodium sulphite Nutrition 0.000 claims description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 235000002949 phytic acid Nutrition 0.000 claims description 3
- 239000000467 phytic acid Substances 0.000 claims description 3
- 229940068041 phytic acid Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- 241001122767 Theaceae Species 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 230000010494 opalescence Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 229940001607 sodium bisulfite Drugs 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 229940001482 sodium sulfite Drugs 0.000 claims 1
- 229940001474 sodium thiosulfate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 18
- 239000002245 particle Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005374 membrane filtration Methods 0.000 description 5
- 239000004530 micro-emulsion Substances 0.000 description 5
- 210000004340 zona pellucida Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种维生素E油纳米乳制剂与制备方法，维生素E纳米乳制剂由维生素E、乳化剂、助乳化剂和溶媒剂组成；本发明的维生素E纳米乳剂，其平均粒径在20nm左右的乳粒有效的解决了制剂的物理稳定性和维生素E油的化学稳定性，降低了它们的毒副作用和不良反应，提高了药物的治疗效果。The invention discloses a vitamin E oil nanoemulsion preparation and a preparation method thereof. The vitamin E nanoemulsion preparation is composed of vitamin E, an emulsifier, a co-emulsifier and a solvent; the vitamin E nanoemulsion of the present invention has an average particle diameter of 20nm The left and right milk particles effectively solve the physical stability of the preparation and the chemical stability of the vitamin E oil, reduce their toxic side effects and adverse reactions, and improve the therapeutic effect of the drug.
Description
Technical field
The present invention relates to a kind of powerful antioxidant, relate in particular to a kind of vitamin E oil nano-emulsion preparation and preparation method.
Background technology
Vitamin E is only by the fat-soluble powerful antioxidant of the synthetic class of photosynthetic organism.Generally be from vegetable oil (oil such as Semen sojae atricolor, Semen Allii Tuberosi, Semen Gossypii, Testa oryzae, corn, sunflower seed, Semen Flos Carthami) refining process, to extract in the deodorization distillate.As far back as 60～seventies of 20th century, researcher just by the biosynthesis of radioisotope labeling research alpha-tocopherol, is illustrated alpha-tocopherol biosynthesis pathway of higher plant and the synthetic site in chloroplast thereof basically to the eighties.Photosynthetic organism is by the series of enzymatic reactions synthetic alpha-tocopherol.The main dosage form of the Vitamin E preparation that existing market is sold has tablet, soft capsule, powder, these four kinds of dosage forms of injection.
Vitamin E is mainly used in defying age, prevention habitual abortion, threatened abortion, menopausal syndrome etc.The auxiliary treatment that also can be used for amyotrophy, muscular dystrophy, hepatitis, liver cirrhosis, coronary heart disease.In recent years along with the progress of vitamin E, exploration to its mechanism of action deepens continuously, clinical application range enlarges day by day, and cardiovascular disease, digestive system disease, ophthalmology illness, tumor, genitourinary system, respiratory system disease, dermatosis and anti-ageing waiting for a long time are all had certain curative effect.
When medicine reached blood system, classical pharmaceutical dosage form (as tablet, ointment, injection) can not be adjusted medicine behavior (distributing and elimination) in vivo.This moment, thereby medicine determined its physicochemical property to influence its biological nature (tissue and plasma protein affinity, membrane receptor affinity and to the sensitivity of enzyme biotransformation etc.) according to its chemical constitution.Modern biopharmaceutics and pharmacokinetic have proved particle when drug delivery system less than 200nm the time, i.e. Nano medication drug-supplying system, and the change of matter will take place in the absorption of drug delivery system and the substrate that turns round.Nano medication can improve drug absorption, change fate of drug, makes medicine have characteristics such as slow release targeting, can improve the curative effect of medicine, reduces untoward reaction, and drug manufacture will realize low cost, high efficiency, automatization and extensive.
Now existing vitamin E tablet, soft gelatin capsule, injection, powder, but at fatsoluble vitamin, vitamin E is prepared into nano-emulsion not only can increase medicine stability, can also improve bioavailability of medicament and curative effect and increase lympha targeted property.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art, a kind of vitamin E oil nano-emulsion preparation and preparation method are provided.
The objective of the invention is to be achieved through the following technical solutions: a kind of vitamin E nano Emulsion, contain the component of following content in this Emulsion: vitamin E 0.1～50g/L, emulsifying agent 2～100g/L, coemulsifier: 1～80g/L, surplus is the solvent agent.
Further, vitamin E is preferably 0.5～30g/L, and emulsifying agent is preferably 5～80g/L, and coemulsifier is preferably 2～50g/L, and surplus is the solvent agent.
Further, described emulsifying agent is one or more the mixing in tween 80, poloxamer and the polyoxyethylene hydrogenated Oleum Ricini; Described co-emulsifier is one or more the mixing in n-butyl alcohol, propylene glycol and the glycerol; Described solvent is one or both the mixing in water and the ethanol.
Further, described vitamin E nano Emulsion also contains additive, and this additive is selected from one or more in antioxidant, antibacterial and the antiseptic; Described antioxidant is selected from: tea polyphenols, phytic acid, sodium sulfite, sodium sulfite, sodium pyrosulfite, sodium thiosulfate; Described antibacterial is selected from: methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzoic acid, sodium benzoate, sorbic acid.
Further, described vitamin E nano Emulsion also contains the pH regulator agent, and this pH value regulator is selected from: sodium hydroxide, potassium chloride, sodium chloride, phosphate, carbonate, citrate, nicotiamide, Benzoylamide.
A kind of preparation method of said vitamin E nano-emulsion comprises the steps:
(1) preparation vitamin E primary emulsion: emulsifying agent and co-emulsifier are stirred, in whipping process, add vitamin E oil then, continue to stir formation milky colostrum, add an amount of solvent agent again, stir, make dissolving fully.
(2) add pH regulator agent and each additive as required, be supplemented to full dose, obtain microemulsion white to being bordering on the opalescent nano-emulsion of zona pellucida with solvent.
(3) filter: the membrane filtration of gained nano-emulsion through 0.22 μ m.
The invention has the beneficial effects as follows:
(1) 90% breast grain particle diameter is no more than 200nm in the nano-emulsion of the present invention, preferably is no more than 20nm, and its mean diameter mostly reaches 0.02 μ m (20nm), is bordering on transparent Emulsion.0.02 the emulsion droplet about μ m belongs to the Emulsion of dynamic stabilization, this vitamin E nano Emulsion can stand autoclaving (121 ℃, 20 minutes), and the content of sterilization back Emulsion does not have significant change.
(2) medicine realizes that by the Nano medication drug-supplying system initiatively target administration is one of main application of administration nano-drug administration system.The mean diameter of this vitamin E nano Emulsion is about 20nm, formed born of the same parents by cytophagy after nano level breast grain enters in the body and draw absorption, the easier arrival focus of the medicine that is cell is better brought into play curative effect, reduces the toxic and side effects of medicine to normal structure or cell simultaneously.
(3) vitamin E nano Emulsion of the present invention, its mean diameter breast grain about 20nm has effectively solved the physical stability of preparation and the chemical stability of vitamin E oil, has reduced their toxic and side effects and untoward reaction, has improved the therapeutic effect of medicine.
Description of drawings
Fig. 1 is the potential measurement of vitamin E nano Emulsion embodiment of the present invention figure as a result;
Fig. 2 is the particle size determination of vitamin E nano Emulsion embodiment of the present invention figure as a result.
The specific embodiment
Vitamin E nano Emulsion of the present invention, wherein 90% breast grain particle diameter is no more than 200nm in the Emulsion; Preferably, be no more than 150nm; More preferably, be no more than 100nm.
Preferably, the mean diameter of this breast grain is no more than 100nm, generally in 10～60nm scope, mostly is about 20～30nm.
Vitamin E nano Emulsion of the present invention, the component that contains following content: vitamin E 0.01～5%, emulsifying agent 0.2～10%, coemulsifier: 0.1～8%, this content is that the gram number in contained each component in every 100mL nano-emulsion is solvent agent polishing to 100% volume.
More preferably vitamin E 0.05～3% in the nano-emulsion of the present invention, emulsifying agent 0.5～8%, coemulsifier: 0.2～5%.
Emulsifying agent is meant and contains hydrophilic, lipophilic group on the molecular structure, can be with oil, the biphase Emulsion that is dispersed into of water under the effect of external force. the present invention is preferably tween 80, poloxamer, polyoxyethylene hydrogenated Oleum Ricini or its mixture.
Coemulsifier is meant that to assist emulsifying agent oil emulsion, water biphase, and it is more small to be simultaneously that particle diameter becomes again, the material that whole emulsifier system is more stable.The preferred n-butyl alcohol of the present invention, propylene glycol, glycerol or its mixture.
Solvent of the present invention is the various water that meet medicinal specification, as water for injection, pure water etc., or ethanol, or water and alcoholic acid mixture, it also can be used as the water and the diluent of Emulsion in prescription.
Certainly, as required, also can in vitamin E nano Emulsion, add various additives, as the pH value regulator: sodium hydroxide, potassium chloride, sodium chloride, phosphate, carbonate, citrate, nicotiamide, Benzoylamide; Be selected from as antioxidant: tea polyphenols, phytic acid, sodium sulfite, sodium sulfite, sodium pyrosulfite, sodium thiosulfate; The antibacterial that need add as unsterilised oral or external preparation time the: methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzoic acid, sodium benzoate, sorbic acid.
The preparation method of vitamin E nano Emulsion of the present invention comprises the steps:
A. vitamin E primary emulsion preparation process: an amount of emulsifying agent and co-emulsifier are stirred, under higher speed stirs, add appropriate vitamin E oil then, continue to stir and form the milky colostrum, add an amount of solvent again, stir, make dissolving fully.
B. add pH regulator agent and each additive as required, the pH that regulates colostrum is supplemented to full dose with solvent about 7.0, obtain microemulsion white to being bordering on the opalescent nanoscale Emulsion of zona pellucida.
C. filtration step: with the membrane filtration of step b gained nano-emulsion, to remove the impurity of greater particle size through 0.22 μ m.
Certainly, preparation method of the present invention also can adopt any existing equipment and technology that is used to prepare nano-emulsion.
Following examples are used to describe the present invention, but not as limitation of the present invention.
Various component raw material in the following example are conventional commercially available prod.
1) accurately take by weighing the 6.75g tween 80,2.25g glycerol on the thermostatic mixer stirs emulsifying agent and co-emulsifier;
2) under higher speed stirs, add the 1g vitamin E oil, continue to stir formation milky colostrum, add an amount of pure water again, stir, make dissolving fully;
3) regulate pH to 7.0 with the sodium hydroxide solution of 0.1mol/L;
4) be supplemented to 100mL with pure water, the volumetric flask standardize solution.Obtain microemulsion white to being bordering on the opalescent nanoscale Emulsion of zona pellucida;
5) nano-emulsion is through the membrane filtration of 0.22 μ m, and filtrate is irritated in suitable brown bottle, the gland encapsulation, promptly.
Embodiment 2
1) accurately take by weighing the 5.6g tween 80,1.4g glycerol on the thermostatic mixer stirs emulsifying agent and co-emulsifier;
2) under higher speed stirs, add the 1g vitamin E oil, continue to stir formation milky colostrum, add an amount of pure water again, stir, make dissolving fully;
3) regulate pH to 7.0 with the sodium hydroxide solution of 0.1mol/L;
4) be supplemented to 100mL with pure water, the volumetric flask standardize solution.Obtain microemulsion white to being bordering on the opalescent nanoscale Emulsion of zona pellucida;
5) nano-emulsion is through the membrane filtration of 0.22 μ m, and filtrate is irritated in suitable brown bottle, the gland encapsulation, promptly.
Embodiment 3
1) accurately take by weighing the 4g tween 80,2g glycerol on the thermostatic mixer stirs emulsifying agent and co-emulsifier;
2) under higher speed stirs, add the 1g vitamin E oil, continue to stir formation milky colostrum, add an amount of pure water again, stir, make dissolving fully;
3) regulate pH to 7.0 with the sodium hydroxide solution of 0.1mol/L;
4) be supplemented to 100mL with pure water, the volumetric flask standardize solution.Obtain microemulsion white to being bordering on the opalescent nanoscale Emulsion of zona pellucida;
5) nano-emulsion is through the membrane filtration of 0.22 μ m, and filtrate is irritated in suitable brown bottle, the gland encapsulation, promptly.
Embodiment 4
Prescription according to embodiment 2 prepares vitamin E nano Emulsion, measures current potential and particle diameter, the results are shown in Figure 1～2.Dilute 5,10,50,100,200 times and measure particle diameter gradually, table 1 shows that its change of size of nano-emulsion dilution back is not obvious as a result, and visible dilution is little to the size influence of nano-emulsion.Dynamic light scattering particle size instrument (Malvern Zetasizer-3000HS, Britain).
Table 1: the size after the nano-emulsion dilution
Prepare vitamin E nano Emulsion according to the prescription of embodiment 2 and carry out influence factor and study on the stability, the result shows that this product is at autoclaving (120 ℃), (60 ℃ of high temperature, 40 ℃), under room temperature (30 ℃, the 25 ℃) condition and illumination (each influence factor of 10 days test under the condition of 4500lx ± 500lx).The results are shown in Table 2～6.Agilent 1100 high performance liquid chromatographs (online degasser, VWD UV-detector, column oven).
Show 2:120 ℃ of heating to V in the nano-emulsion
EThe influence of content (n=3)
Table 3:V
ENano-emulsion high temperature (60 ℃) influence factor test
Table 4:V
ENano-emulsion high temperature (40 ℃) influence factor test
Table 5:V
E30 ℃ of tests of nano-emulsion and 25 ℃ of tests of room temperature (n=3)
Table 6:V
ENano-emulsion high light influence factor test
The foregoing description is used for the present invention that explains, rather than limits the invention, and in the protection domain of spirit of the present invention and claim, any modification and change to the present invention makes all fall into protection scope of the present invention.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910154931A CN101703468A (en) | 2009-11-30 | 2009-11-30 | Nano-emulsion of vitamin E oil and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910154931A CN101703468A (en) | 2009-11-30 | 2009-11-30 | Nano-emulsion of vitamin E oil and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101703468A true CN101703468A (en) | 2010-05-12 |
Family
ID=42373765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910154931A Pending CN101703468A (en) | 2009-11-30 | 2009-11-30 | Nano-emulsion of vitamin E oil and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101703468A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982176A (en) * | 2010-10-18 | 2011-03-02 | 齐鲁动物保健品有限公司 | Compound sodium selenite-vitamin E oral nano-emulsion preparation for livestock and preparation method thereof |
| CN102551056A (en) * | 2012-01-10 | 2012-07-11 | 江南大学 | O/W (Water in Oil) type microemulsion model of fat-soluble nutrient with carbon chain length of (15 and preparation method thereof |
| CN104707499A (en) * | 2015-02-13 | 2015-06-17 | 西北农林科技大学 | Preparation method for nonionic bitter almond oil microemulsion |
| CN105168129A (en) * | 2015-07-29 | 2015-12-23 | 山东迅达康生物科技有限公司 | Vitamin E nanoemulsion and preparation method thereof |
| CN105726478A (en) * | 2016-01-28 | 2016-07-06 | 武汉欧米嘉生物医药有限公司 | Oral EPA(Eicoeapentaenoic acid) O/W type nanoemulsion and preparation method thereof |
| CN105813480A (en) * | 2013-12-11 | 2016-07-27 | 帝斯曼知识产权资产管理有限公司 | A nutritional reinforced composition and a process for preparation thereof |
| CN106389152A (en) * | 2016-08-24 | 2017-02-15 | 登封市科创商务咨询有限公司 | Vitamin E nourishing and skin-care lotion |
| CN107115349A (en) * | 2017-05-05 | 2017-09-01 | 宁夏智弘生物科技有限公司 | A kind of vitaminAD E microemulsion injections for animals and preparation method thereof |
| CN107802512A (en) * | 2017-12-07 | 2018-03-16 | 武汉大学 | A kind of vitamin E nano-emulsion, nanometer emulsifiable paste and preparation method thereof |
-
2009
- 2009-11-30 CN CN200910154931A patent/CN101703468A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982176A (en) * | 2010-10-18 | 2011-03-02 | 齐鲁动物保健品有限公司 | Compound sodium selenite-vitamin E oral nano-emulsion preparation for livestock and preparation method thereof |
| CN101982176B (en) * | 2010-10-18 | 2012-07-04 | 齐鲁动物保健品有限公司 | Compound sodium selenite-vitamin E oral nano-emulsion preparation for livestock and preparation method thereof |
| CN102551056A (en) * | 2012-01-10 | 2012-07-11 | 江南大学 | O/W (Water in Oil) type microemulsion model of fat-soluble nutrient with carbon chain length of (15 and preparation method thereof |
| CN105813480A (en) * | 2013-12-11 | 2016-07-27 | 帝斯曼知识产权资产管理有限公司 | A nutritional reinforced composition and a process for preparation thereof |
| CN104707499A (en) * | 2015-02-13 | 2015-06-17 | 西北农林科技大学 | Preparation method for nonionic bitter almond oil microemulsion |
| CN105168129A (en) * | 2015-07-29 | 2015-12-23 | 山东迅达康生物科技有限公司 | Vitamin E nanoemulsion and preparation method thereof |
| CN105168129B (en) * | 2015-07-29 | 2018-02-23 | 山东迅达康生物科技有限公司 | A kind of vitamin E nano-emulsion and preparation method thereof |
| CN105726478A (en) * | 2016-01-28 | 2016-07-06 | 武汉欧米嘉生物医药有限公司 | Oral EPA(Eicoeapentaenoic acid) O/W type nanoemulsion and preparation method thereof |
| CN106389152A (en) * | 2016-08-24 | 2017-02-15 | 登封市科创商务咨询有限公司 | Vitamin E nourishing and skin-care lotion |
| CN107115349A (en) * | 2017-05-05 | 2017-09-01 | 宁夏智弘生物科技有限公司 | A kind of vitaminAD E microemulsion injections for animals and preparation method thereof |
| CN107802512A (en) * | 2017-12-07 | 2018-03-16 | 武汉大学 | A kind of vitamin E nano-emulsion, nanometer emulsifiable paste and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703468A (en) | Nano-emulsion of vitamin E oil and preparation method thereof | |
| Zhang et al. | Self-emulsifying drug delivery system and the applications in herbal drugs | |
| Li et al. | Formulation, biological and pharmacokinetic studies of sucrose ester-stabilized nanosuspensions of oleanolic acid | |
| Hong et al. | Annonaceous acetogenins nanosuspensions stabilized by PCL-PEG block polymer: significantly improved antitumor efficacy | |
| CN106256345A (en) | Vitamin C delivery system and liposome composition thereof | |
| CN104337859B (en) | A kind of licorice flavonoid self-microemulsion composition and preparation method thereof | |
| CN101780037B (en) | Dipyridamole self-emulsifying medicament administration system and preparation method thereof | |
| WO2017045034A1 (en) | Ubiquinone and ubiquinol compositions, and methods relating thereto | |
| CN114796110A (en) | Insoluble drug concentrated solution without ethanol and micelle solution prepared from insoluble drug concentrated solution | |
| Shailendrakumar et al. | Improved oral pharmacokinetics of pentoxifylline with palm oil and capmul® MCM containing self-nano-emulsifying drug delivery system | |
| CN106619588A (en) | Self-microemulsion nutrient composition containing coenzyme Q10 and preparation method and application | |
| Lu et al. | Characterization and evaluation of an oral microemulsion containing the antitumor diterpenoid compound ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid | |
| US20120141446A1 (en) | Oral Nutritional Supplement Delivery System | |
| Provenzano et al. | Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies | |
| CN102631400A (en) | Compound minoxidil nano-emulsion antihypertensive medicament | |
| TWI542342B (en) | Use, pharmaceutical composition and manifacturing method thereof for applying resveratrol and curcumin in fatty liver treatment | |
| Liu et al. | Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension | |
| WO2022027053A1 (en) | Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality | |
| CN102657697A (en) | Propranolol-eugenol type basil oil nano-emulsion medicament and preparation method thereof | |
| CN118304270B (en) | Vitamin D drop and preparation method thereof | |
| US12011470B2 (en) | Micelle preparations of full-spectrum hemp oil | |
| CN116531478B (en) | Paclitaxel-traditional Chinese medicine grease composite emulsion and preparation method and application thereof | |
| US11826320B2 (en) | Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm | |
| CN104274499A (en) | Oil-in-water type compound minocyline antibacterial medicine | |
| CN100358506C (en) | Compound musk drip pill and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100512 |